REGN
NasdaqREGENERON PHARMACEUTICALS, INC.
Health Care, Biotechnology
$784.36
close 7 Aug 2026
+43.67%
52-week change
$80.75B
market cap
$541.00
$821.11
52-week range
| Line item | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||||||||||||
| Revenue | $15.53B | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | $2.10B | $1.38B | $445.82M | $459.07M | $379.27M | $238.46M |
| Cost of revenue | — | — | — | — | — | — | — | $402.80M | $237.50M | $202.51M | $194.62M | $241.70M | $129.03M | $118.05M | $83.93M | $4.22M | $2.09M | $1.69M | $923.00K |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| R&D | $6.28B | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B | $2.08B | $2.05B | $1.62B | $1.27B | $859.95M | $625.55M | $529.51M | $489.25M | $398.76M | $274.90M |
| SG&A | $2.74B | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B | $1.32B | $1.18B | $838.53M | $519.27M | $346.39M | $210.76M | $117.26M | $65.20M | $52.92M | $48.88M |
| Operating income | $3.84B | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B | $1.25B | $823.92M | $743.05M | $457.71M | -$205.16M | -$97.47M | -$74.10M | -$86.25M |
| Interest expense | $55.40M | $43.80M | $55.20M | $73.00M | $59.40M | $57.30M | $56.90M | $30.20M | $28.20M | $25.10M | $7.20M | $14.24M | $37.37M | $46.44M | $45.30M | $21.28M | $9.12M | $2.34M | $7.75M |
| Tax expense | $837.30M | $725.80M | $367.30M | $245.70M | $520.40M | $1.25B | $297.20M | $313.30M | $109.10M | $880.00M | $434.30M | $589.04M | $423.11M | $282.64M | -$335.85M | -$1.13M | $0.00 | -$4.12M | $2.35M |
| Net income | $4.33B | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $895.50M | $636.06M | $338.13M | $413.74M | $750.27M | -$221.76M | -$104.47M | -$67.83M | -$79.13M |
| Diluted EPS | $40.38 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | $3.72 | $6.75 | -$2.45 | -$1.26 | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 24.74% | 24.95% | 28.10% | 30.85% | 38.93% | 55.67% | 42.09% | 33.70% | 49.25% | 35.41% | 27.38% | 30.51% | 29.22% | 35.30% | 33.20% | -46.02% | -21.23% | -19.54% | -36.17% |
| Net margin | 27.86% | 31.41% | 31.07% | 30.14% | 35.64% | 50.25% | 41.35% | 32.26% | 47.50% | 20.41% | 18.42% | 15.50% | 11.99% | 19.66% | 54.43% | -49.74% | -22.76% | -17.88% | -33.18% |
filed 30 Jul 2026